Patents by Inventor Kenneth Flanagan

Kenneth Flanagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Laminin4 antibodies specific for LG4-5
    Patent number: 10889636
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 12, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Anti-MCAM Antibodies And Associated Methods Of Use
    Publication number: 20200216560
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: January 16, 2020
    Publication date: July 9, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • MCAM ANTAGONISTS AND METHODS OF TREATMENT
    Publication number: 20200165336
    Abstract: Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin a4 chain, e.g., an ct4 chain of laminin 41 1. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH 17 cells into the CNS.
    Type: Application
    Filed: November 21, 2019
    Publication date: May 28, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jennifer Johnston, Theodore Yednock, Jeanne Baker
  • Anti-laminin4 antibodies specific for LG4-5
    Patent number: 10654920
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: May 19, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Anti-MCAM antibodies and associated methods of use
    Patent number: 10584177
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 10, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Anti-MCAM antibodies and associated methods of use
    Patent number: 10414825
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 17, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Anti-MCAM antibodies and associated methods of use
    Patent number: 10407507
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 10, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • ANTI-LAMININ4 ANTIBODIES SPECIFIC FOR LG4-5
    Publication number: 20180371067
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 27, 2018
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Anti-Laminin4 antibodies specific for LG4-5
    Patent number: 10059761
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: August 28, 2018
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • ANTI-LAMININ4 ANTIBODIES SPECIFIC FOR LG4-5
    Publication number: 20180208646
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 26, 2018
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Anti-MCAM Antibodies And Associated Methods Of Use
    Publication number: 20180105602
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: October 5, 2017
    Publication date: April 19, 2018
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • ANTI-LAMININ4 ANTIBODIES SPECIFIC FOR LG1-3
    Publication number: 20170158755
    Abstract: The invention provides antibodies that specifically bind to the LG1-3 modules of the G domain of laminin ?4. The antibodies have the capacity to inhibit binding of laminin ?4 to MCAM. The antibodies can be used for inhibiting undesired immune responses, treatment of cancer, or treatment of obesity or obesity-related diseases, among other applications.
    Type: Application
    Filed: March 12, 2015
    Publication date: June 8, 2017
    Applicant: Prothena Biosciences Limited
    Inventors: Kenneth Flanagan, Stephen Jed Tam, Yue Liu, Theodore Yednock, Robin Barbour
  • Anti-MCAM Antibodies And Associated Methods Of Use
    Publication number: 20170145109
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: July 28, 2016
    Publication date: May 25, 2017
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
    Publication number: 20170129954
    Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
    Type: Application
    Filed: September 16, 2016
    Publication date: May 11, 2017
    Inventor: KENNETH FLANAGAN
  • Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
    Publication number: 20170101470
    Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
    Type: Application
    Filed: September 16, 2016
    Publication date: April 13, 2017
    Inventors: Yue Liu, Patrick Garidel, Andreas Langer, Kenneth Flanagan
  • Anti-MCAM Antibodies And Associated Methods Of Use
    Publication number: 20170037144
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 9, 2017
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Anti-MCAM antibodies and associated methods of use
    Patent number: 9447190
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: September 20, 2016
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
    Publication number: 20150239980
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 27, 2015
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • MCAM ANTAGONISTS AND METHODS OF TREATMENT
    Publication number: 20140314744
    Abstract: Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin ?4 chain, e.g., an ?4 chain of laminin 411. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH17 cells into the CNS.
    Type: Application
    Filed: June 6, 2012
    Publication date: October 23, 2014
    Applicant: Neotope Biosciences Limited
    Inventors: Kenneth Flanagan, Jennifer Johnston, Theodore Yednock, Jeanne Baker
  • Anti-MCAM Antibodies And Associated Methods Of Use
    Publication number: 20140227292
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 14, 2014
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock